Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

Vanessa Caceres  |  Issue: February 2017  |  February 15, 2017

“This study emphasizes that some patients are at risk of poorly managing their biologic therapy. These patients should be identified and monitored to avoid major and perhaps life-threatening complications,” Dr. Rat says.

Rheumatologists and their staff may need to remind patients more frequently about some of the misuse risks, Dr. Rat cautions.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Rheumatologists should remind patients to have patience with biologics in terms of allowing for effectiveness, managing side effects, and getting over the fear of self-injection, Dr. Askanase says.

5 Tips to Improve the Patient Education Discussion

1. Ask patients to bring a family member or friend with them, Dr. Troum advises. This gives the patient—who likely is still processing information about their disease—an objective person who will listen and ask questions regarding biologics. When a patient comes to the office alone initially, this sometimes means they must return for a second appointment to bring their companion. Dr. Troum is fine with this if it means they will be better informed about biologics.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

2. Update your approach as needed. Dr. Huston finds that focusing too much on the risks of biologics scares patients away and that a balanced discussion of benefits and risks is typically needed. He also finds that patients often have preconceived notions about the medication and need their misinformation corrected. He alters his discussion based on perceived patient fears and preferences. “Some patients express a lot of anxiety and want to review biologic therapy in great detail, and others just say, ‘Whatever you think is best, doc,’” Dr. Huston says.

You may also change your education depending on patients’ lifestyle issues and financial challenges, Dr. Field says.

3. Tap into seasoned patients as resources for new patients. “Developing a ‘network’ can be a game-changer for my patients,” Dr. Field says. “We have our experienced patients available for support to our newly diagnosed patients. Patients considering biologics can tour our infusion suite and are encouraged to chat with patients who are receiving infusion therapy at that very moment,” Dr. Field says. “Many patients develop friendships that are quite helpful through their RA treatment journey.”

4. Think about new, useful ways to present medication information. In addition to the usual discussion and written material, the U.S. National Library of Medicine suggests several other teaching tools, including podcasts, YouTube or other videos, PowerPoint presentations, posters or charts, models or props, group classes and trained peer educators.

“Appropriate, effective patient education really requires a multidisciplinary and integrative approach using several modalities,” Ms. Batterman says. For example, support and education programs offer an opportunity to obtain support from peers who understand the complex concerns of fellow patients, with the benefit of healthcare professionals gently guiding the discussion. Nurses can provide further clarification and answer questions; social workers can assess and further explore issues around coping with chronic illness and treatment, which can impact patients’ understanding, decisions and adherence in a profound way.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:Association of Rheumatology Professionals (ARP)BiologicsDrugspatient carePractice ManagementQualityrheumatologistrheumatologySafetytherapyTreatment

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences